<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Not recommended with:</SEVERITY>
<COMMENT>-anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3 gr per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS" code="B01A-001" /></DRUG2>
<DESCRIPTION>Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the Vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) in large doses or in treatment prolonged beyond 10 days. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When administering substances from these groups together is justified, strengthen monitoring: if the situation requires, with the vitamin K antagonists, biological testing on the 8th day, then every two weeks after that during the corticotherapy and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYMATIC INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have Addisons disease treated with hydrocortisone and in cases of organ transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the inducer and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of ulceration and of gastrointestinal hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="NON-DEPOLARIZING CURARES" code="M03A-002" /></DRUG2>
<DESCRIPTION>With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving corticotherapy for a prolonged period</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for prednisolone. 

Decrease of the plasma concentrations of the isoniazid. Mechanism proposed: increase of the hepatic metabolism of the isoniazid and decrease of that of the glucocorticoides</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring; adjustment of the dosage of the corticoids during the treatment with the rifampicin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG1>
<DRUG2>
<CLASS name="ATTENUATED LIVE VIRUS VACCINES" code="J07B-001" /></DRUG2>
<DESCRIPTION>With the exception of inhaled and local routes, and for doses greater than 10mg/day of prednisone-equivalent (or &gt; 2mg/kg/day for a child or &gt; 20mg/day for a child weighing more than 10 kg) during more than two weeks and for the &quot;bolus&quot; of corticoids: risk of possibly fatal general vaccine disease.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>And during the 3 months following the end of the therapy with the corticoid.</COMMENT>
</INTERACTION>
</INTERACTIONS>
